# Cara Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cara-therapeutics

- Industry: Biotechnology
- Headquarters: Stamford, US
- Website: www.caratherapeutics.com
- Total disclosed funding: $51M
- Latest round: Series D (Jul 19, 2010)
- Investors on record: 9

## About

Cara Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapeutics for patients suffering from pain and pruritus through its proprietary technology that targets the body's opioid system.Founded in 2004 in Shelton, US, Cara Therapeutics Inc. focuses on developing novel treatments for pain and itch management. The company has raised a total of USD 0.10 mn through a PIPE funding round, with the most recent deal occurring on January 31, 2014. The current CEOs are Chris Posner and Derek Chalmers.Cara Therapeutics specializes in creating therapeutics that target the body's opioid receptors to alleviate various types of pain and itch. Their primary products are designed to offer effective treatment options for patients suffering from acute pain conditions and chronic pruritus, primarily serving healthcare providers and hospitals.In the most recent year of 2023, Cara Therapeutics reported revenue of USD 20.27 mn and an EBITDA of USD -121.89 mn, reflecting ongoing investments in research and development within the therapeutic landscape.Cara Therapeutics aims to expand its product offerings by introducing new therapies targeting additional pain and itch conditions, with ongoing development efforts slated for the coming years. The company is also looking to enter new geographic markets, focusing on Europe and certain regions of Asia by 2025. The funds raised in their PIPE round will be utilized to support these development initiatives and market expansion efforts.

## Funding rounds

- Series D, Jul 19, 2010, $15M — Alta Partners, HealthCare Ventures, MVM Partners, RHO, Ascent Biomedical Ventures, MIC Capital, Devon Park Bioventures, Connecticut Innovations
- Series C, Jul 24, 2008, $12M — Ascent Biomedical Ventures, MIC Capital, Devon Park Bioventures, Connecticut Innovations
- Series C, Nov 28, 2006, $19M — Alta Partners, MVM Partners, Ascent Biomedical Ventures
- Series B, Dec 21, 2005, $4.7M — Ascent Biomedical Ventures, Esperante Ventures

## Investors

- Ascent Biomedical Ventures (https://capitalatlas.ai/funds/ascent-biomedical-ventures) — Series B, Series C, Series D
- Esperante Ventures (https://capitalatlas.ai/funds/esperante-ventures) — Series B
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C, Series D
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series C, Series D
- MIC Capital — Series C, Series D
- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series C, Series D
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series C, Series D
- HealthCare Ventures — Series D
- RHO (https://capitalatlas.ai/funds/rho) — Series D